Lamivudine/nevirapine/stavudine
| Combination of | |
|---|---|
| Lamivudine | nucleoside reverse transcriptase inhibitor |
| Nevirapine | non-nucleoside reverse transcriptase inhibitor |
| Stavudine | nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Trade names | Triomune, others |
| ATC code | |
| Identifiers | |
| ChemSpider |
|
Lamivudine/nevirapine/stavudine (3TC/NVP/d4T) is a medication used to treat HIV/AIDS.[1] It is a fixed dose combination of lamivudine, nevirapine, and stavudine.[1] It is either used by itself or along with other antiretrovirals.[1] It is taken by mouth twice a day.[1]
The medication is generally well tolerated.[2] Side effects are those of the underlying medications.[1] This may include rash, numbness, pancreatitis, and high blood lactate levels.[2] Use is not recommended in those with significant liver problems.[2] It is unclear if use in pregnancy is safe for the baby and recommendations include starting in the second trimester if possible.[2]
It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[3] The wholesale cost in the developing world is about 9.56 USD per month.[4] As of 2015 it is not commercially available in the United States.[5]
Medical uses
It is a common first line treatment in the developing world.[6]
References
- ^ a b c d e WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 160. ISBN 9789241547659. Archived from the original (PDF) on 13 December 2016. Retrieved 8 December 2016.
{{cite book}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ a b c d "Nevirapine/stavudine/lamivudine" (PDF). aidsmap. Archived from the original (PDF) on 20 December 2016. Retrieved 18 December 2016.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived from the original (PDF) on 13 December 2016. Retrieved 8 December 2016.
{{cite web}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ "Lamivudine + Stavudine + Nevirapine". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- ^ Kasper, Dennis L.; Fauci, Anthony S.; Hauser, Stephen; Longo, Dan; Jameson, J. Larry; Loscalzo, Joseph (2015). Harrison's Principles of Internal Medicine 19/E (Vol.1 & Vol.2). McGraw Hill Professional. p. 1277. ISBN 9780071802161. Archived from the original on 2016-12-20.
{{cite book}}: Unknown parameter|deadurl=ignored (|url-status=suggested) (help) - ^ Siegfried, NL; Van Deventer, PJ; Mahomed, FA; Rutherford, GW (19 April 2006). "Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults". The Cochrane Database of Systematic Reviews (2): CD004535. PMID 16625606.
